Timing of Peak Troponin T and Creatine Kinase-MB Elevations after Percutaneous Coronary Intervention

Wayne L. Miller, Kirk N. Garratt, Mary F. Burritt, Guy S. Reeder, Allan S Jaffe

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Study objective: The prognostic significance of elevations in creatine kinase-MB and troponin T (cTnT), which have been conventionally measured 6 to 8 h after percutaneous coronary intervention (PCI), has been established. However, the time to peak biomarker appearance in the circulation has not been defined and is the purpose of this pilot study. Design: Nonrandomized, nonconsecutive patient cohort. Setting: Clinical practice, Mayo Clinic, Rochester, MN. Patients: Cohort (n = 57) undergoing elective PCI. Interventions: cTnT and creatine kinase (CK)-MB measured at baseline, 2 h, 4 h, 8 h, and ≥ 12 h (mean ± SEM, 18 ± 5 h) after PCI. Measurements and results: Postprocedure cTnT elevations were detected in 30 of 57 patients (53%). Of these, 4 of 30 patients (13%) had peak cTnT at 4 h (0.80 ± 0.40 ng/mL), 5 of 30 patients (17%) had peak cTnT at 8 h (1.07 ± 0.48 ng/mL), and 21 of 30 patients (70%) had peak cTnT at ≥ 12 h (0.21 ± 0.06 ng/mL); 22 of 30 patients received abciximab. Elevations in CK-MB occurred in 14 of 57 patients (25%). Of these, 3 of 14 patients (21%) demonstrated peak CK-MB at 2 h (18.5 ± 7.9 ng/mL) and the remainder (11 of 14 patients, 79%) during the 12- to 20-h interval (20.2 ± 4.4 ng/mL); 12 of 14 patients received abciximab. Conclusion: More cTnT than CK-MB elevations occur after PCI; however, both biomarkers demonstrate a longer time to peak value than anticipated in clinical practice. Early surveillance monitoring (< 12 h) does not detect peak biomarker levels, especially in patients with normal baseline values. If peak levels are to be used to determine prognosis, then longer time intervals should be used for post-PCI surveillance. The timing of peak elevations appears to be influenced by baselines values as well. Early elevations may reflect the conjoint effects of injury associated with the disease process and the intervention itself. These data suggest that a re-evaluation of surveillance monitoring to account for the variability reported and the influence of baseline elevations of biomarkers may improve the prognostic power of the measurements.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalChest
Volume125
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

MB Form Creatine Kinase
Troponin T
Percutaneous Coronary Intervention
Biomarkers
Creatine Kinase
Reference Values

Keywords

  • Biomarkers
  • Coronary artery disease
  • Creatine kinase-MB
  • Peak values
  • Percutaneous coronary intervention
  • Troponin T

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Timing of Peak Troponin T and Creatine Kinase-MB Elevations after Percutaneous Coronary Intervention. / Miller, Wayne L.; Garratt, Kirk N.; Burritt, Mary F.; Reeder, Guy S.; Jaffe, Allan S.

In: Chest, Vol. 125, No. 1, 01.2004, p. 275-280.

Research output: Contribution to journalArticle

Miller, Wayne L. ; Garratt, Kirk N. ; Burritt, Mary F. ; Reeder, Guy S. ; Jaffe, Allan S. / Timing of Peak Troponin T and Creatine Kinase-MB Elevations after Percutaneous Coronary Intervention. In: Chest. 2004 ; Vol. 125, No. 1. pp. 275-280.
@article{a1eba0a6cb6d4f43ae77442433eb1881,
title = "Timing of Peak Troponin T and Creatine Kinase-MB Elevations after Percutaneous Coronary Intervention",
abstract = "Study objective: The prognostic significance of elevations in creatine kinase-MB and troponin T (cTnT), which have been conventionally measured 6 to 8 h after percutaneous coronary intervention (PCI), has been established. However, the time to peak biomarker appearance in the circulation has not been defined and is the purpose of this pilot study. Design: Nonrandomized, nonconsecutive patient cohort. Setting: Clinical practice, Mayo Clinic, Rochester, MN. Patients: Cohort (n = 57) undergoing elective PCI. Interventions: cTnT and creatine kinase (CK)-MB measured at baseline, 2 h, 4 h, 8 h, and ≥ 12 h (mean ± SEM, 18 ± 5 h) after PCI. Measurements and results: Postprocedure cTnT elevations were detected in 30 of 57 patients (53{\%}). Of these, 4 of 30 patients (13{\%}) had peak cTnT at 4 h (0.80 ± 0.40 ng/mL), 5 of 30 patients (17{\%}) had peak cTnT at 8 h (1.07 ± 0.48 ng/mL), and 21 of 30 patients (70{\%}) had peak cTnT at ≥ 12 h (0.21 ± 0.06 ng/mL); 22 of 30 patients received abciximab. Elevations in CK-MB occurred in 14 of 57 patients (25{\%}). Of these, 3 of 14 patients (21{\%}) demonstrated peak CK-MB at 2 h (18.5 ± 7.9 ng/mL) and the remainder (11 of 14 patients, 79{\%}) during the 12- to 20-h interval (20.2 ± 4.4 ng/mL); 12 of 14 patients received abciximab. Conclusion: More cTnT than CK-MB elevations occur after PCI; however, both biomarkers demonstrate a longer time to peak value than anticipated in clinical practice. Early surveillance monitoring (< 12 h) does not detect peak biomarker levels, especially in patients with normal baseline values. If peak levels are to be used to determine prognosis, then longer time intervals should be used for post-PCI surveillance. The timing of peak elevations appears to be influenced by baselines values as well. Early elevations may reflect the conjoint effects of injury associated with the disease process and the intervention itself. These data suggest that a re-evaluation of surveillance monitoring to account for the variability reported and the influence of baseline elevations of biomarkers may improve the prognostic power of the measurements.",
keywords = "Biomarkers, Coronary artery disease, Creatine kinase-MB, Peak values, Percutaneous coronary intervention, Troponin T",
author = "Miller, {Wayne L.} and Garratt, {Kirk N.} and Burritt, {Mary F.} and Reeder, {Guy S.} and Jaffe, {Allan S}",
year = "2004",
month = "1",
doi = "10.1378/chest.125.1.275",
language = "English (US)",
volume = "125",
pages = "275--280",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Timing of Peak Troponin T and Creatine Kinase-MB Elevations after Percutaneous Coronary Intervention

AU - Miller, Wayne L.

AU - Garratt, Kirk N.

AU - Burritt, Mary F.

AU - Reeder, Guy S.

AU - Jaffe, Allan S

PY - 2004/1

Y1 - 2004/1

N2 - Study objective: The prognostic significance of elevations in creatine kinase-MB and troponin T (cTnT), which have been conventionally measured 6 to 8 h after percutaneous coronary intervention (PCI), has been established. However, the time to peak biomarker appearance in the circulation has not been defined and is the purpose of this pilot study. Design: Nonrandomized, nonconsecutive patient cohort. Setting: Clinical practice, Mayo Clinic, Rochester, MN. Patients: Cohort (n = 57) undergoing elective PCI. Interventions: cTnT and creatine kinase (CK)-MB measured at baseline, 2 h, 4 h, 8 h, and ≥ 12 h (mean ± SEM, 18 ± 5 h) after PCI. Measurements and results: Postprocedure cTnT elevations were detected in 30 of 57 patients (53%). Of these, 4 of 30 patients (13%) had peak cTnT at 4 h (0.80 ± 0.40 ng/mL), 5 of 30 patients (17%) had peak cTnT at 8 h (1.07 ± 0.48 ng/mL), and 21 of 30 patients (70%) had peak cTnT at ≥ 12 h (0.21 ± 0.06 ng/mL); 22 of 30 patients received abciximab. Elevations in CK-MB occurred in 14 of 57 patients (25%). Of these, 3 of 14 patients (21%) demonstrated peak CK-MB at 2 h (18.5 ± 7.9 ng/mL) and the remainder (11 of 14 patients, 79%) during the 12- to 20-h interval (20.2 ± 4.4 ng/mL); 12 of 14 patients received abciximab. Conclusion: More cTnT than CK-MB elevations occur after PCI; however, both biomarkers demonstrate a longer time to peak value than anticipated in clinical practice. Early surveillance monitoring (< 12 h) does not detect peak biomarker levels, especially in patients with normal baseline values. If peak levels are to be used to determine prognosis, then longer time intervals should be used for post-PCI surveillance. The timing of peak elevations appears to be influenced by baselines values as well. Early elevations may reflect the conjoint effects of injury associated with the disease process and the intervention itself. These data suggest that a re-evaluation of surveillance monitoring to account for the variability reported and the influence of baseline elevations of biomarkers may improve the prognostic power of the measurements.

AB - Study objective: The prognostic significance of elevations in creatine kinase-MB and troponin T (cTnT), which have been conventionally measured 6 to 8 h after percutaneous coronary intervention (PCI), has been established. However, the time to peak biomarker appearance in the circulation has not been defined and is the purpose of this pilot study. Design: Nonrandomized, nonconsecutive patient cohort. Setting: Clinical practice, Mayo Clinic, Rochester, MN. Patients: Cohort (n = 57) undergoing elective PCI. Interventions: cTnT and creatine kinase (CK)-MB measured at baseline, 2 h, 4 h, 8 h, and ≥ 12 h (mean ± SEM, 18 ± 5 h) after PCI. Measurements and results: Postprocedure cTnT elevations were detected in 30 of 57 patients (53%). Of these, 4 of 30 patients (13%) had peak cTnT at 4 h (0.80 ± 0.40 ng/mL), 5 of 30 patients (17%) had peak cTnT at 8 h (1.07 ± 0.48 ng/mL), and 21 of 30 patients (70%) had peak cTnT at ≥ 12 h (0.21 ± 0.06 ng/mL); 22 of 30 patients received abciximab. Elevations in CK-MB occurred in 14 of 57 patients (25%). Of these, 3 of 14 patients (21%) demonstrated peak CK-MB at 2 h (18.5 ± 7.9 ng/mL) and the remainder (11 of 14 patients, 79%) during the 12- to 20-h interval (20.2 ± 4.4 ng/mL); 12 of 14 patients received abciximab. Conclusion: More cTnT than CK-MB elevations occur after PCI; however, both biomarkers demonstrate a longer time to peak value than anticipated in clinical practice. Early surveillance monitoring (< 12 h) does not detect peak biomarker levels, especially in patients with normal baseline values. If peak levels are to be used to determine prognosis, then longer time intervals should be used for post-PCI surveillance. The timing of peak elevations appears to be influenced by baselines values as well. Early elevations may reflect the conjoint effects of injury associated with the disease process and the intervention itself. These data suggest that a re-evaluation of surveillance monitoring to account for the variability reported and the influence of baseline elevations of biomarkers may improve the prognostic power of the measurements.

KW - Biomarkers

KW - Coronary artery disease

KW - Creatine kinase-MB

KW - Peak values

KW - Percutaneous coronary intervention

KW - Troponin T

UR - http://www.scopus.com/inward/record.url?scp=1642534552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642534552&partnerID=8YFLogxK

U2 - 10.1378/chest.125.1.275

DO - 10.1378/chest.125.1.275

M3 - Article

C2 - 14718451

AN - SCOPUS:1642534552

VL - 125

SP - 275

EP - 280

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -